Изучение ноотропной и нейропротективной активности веществ, воздействующих на глутаматергическую систему
Диссертация
Позитивное фармакологическое воздействие препаратов с ноотропной и нейропротективной активностью на когнитивные функции в опытах на поведенческих моделях имеет электрофизиологические корреляты в виде облегчения потенциации и пролонгирования LTP в гиппокампе. Нооглютил в срезах гиппокампа пролонгировал NMDA — зависимую LTP в синапсах, образованных аксонами перфорантного пути и на нейронах зубчатой… Читать ещё >
Список литературы
- Абаимов Д. А. Автореферат дис. канд. наук. Москва (2007).
- Абрамец И.И., Комиссаров И. В., Король Т. И., Самойлович И. И. Исследования влияния ноотропных средств на глутаматергическую синаптическую передачу в срезах гиппокампа крыс. Архив клинической и экспериментальной медицины, т. 3, с. 3- 18,(1994).
- Алиев О.И., Плотникова Т. М., Воронина Т. А., Плотников М. Б. Влияние нооглютила на локальный мозговой кровоток и ЭЭГ крыс в условиях ишемии мозга. Бюллетень экспериментальной биологии и медицины, приложение 1, с. 12- 15,(1999).
- Андронова В.Л. Антибиотики и химотерапия. т.41. № 718. с. 26−30 (1996).
- Багрин Е.И. Адатантаны: получение, свойства, применение. М.:Наука (1989).
- Барыгин О.И., Иванов О. И. Николаев М.В. Взаимодействие конкурентных и неконкурентных антагонистов с ионотропными глутаматергическим и рецепторами, Вестник молодых ученых, № 1, С. 11−19 (2004).
- Беспалов А.Ю., Эвартау Э. Э. Нейропсихофармакология антагонистов NMDA-рецепторов, Санкт-Петербург, 296 с. (2000).
- Буреш Я., Бурешова О., Хьюстон Д. П. Методики и основные эксперименты по изучению мозга и поведения. М.: Высш. школа (1991).
- Буров Ю.В., Робакидзе Т. Н., Кадышева А. Е. Изучение антиамнестической активности амиридина на модели амнестического синдрома. Бюллетень экспериментальной биологии и медицины. Т. 111, № 6, с. 614 617, (1991).
- Воронина Т.А. Гипоксия и память. Особенности эффектов и применения ноотропных средств. Вестник российской академии медицинских наук. Т. 9, с. 27 33 (2000).
- П.Воронина Т. А. Новые ноотропные препараты с нейропротективной активностью. Психофармакологияи биологическая наркология. Т.2, № 3−4, с. 375 (2002).
- Воронина Т.А. Спектр фармакологической активности гидазепама и его место среди известных транквилизаторов. Гидазепам., Киев: Наукова Думка, Ред. Андронати С. А., Воронина Т. А., Головенко Н. Я. с. 63 75 (1992).
- Воронина Т.А., Гузеватых JI.C., Трофимов С. С. Сравнение отдаленных поведенческих последствий применения ноопепта и парацетама в ранний постнатальный период у крыс. Экспериментальная и клиническая фармакология. № 2. С.3−7 (2005).
- Воронина Т.А., Островская Р. У. Методические указания по изучению ноотропной шстивности фармакологических веществ // В книге: Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. Москва, с. 153 158 (2000).
- Воронина Т.А., Середенин С. Б. Ноотропные и иейропротективные средства. Экспер. и клин, фармакол. Т. 70(4), с. 44−58 (2007).
- Гаврилова С.И. Болезнь Альцгеймера: новые терапевтические возможности. Consilium Medicum. Т.6, N.2,c.l42−149 (2004).
- Ганнушкина И.В., Функциональная ангиоархитектоника головного мозга. Медицина, Москва, с. 224 (1977).
- Гарибова Т.П., Галаева И. П., Воронина Т. А., и соавт. Эффект нооглютила у крыс с интрацеребральной постгравматической гематомы (геморрагическим инсультом). Экспер. и клин. Фармакол. Т.66. № 2, с. 45−48 (2003).
- Галаева И.Н. Автореф. дисс. канд. наук. Москва (2004).
- Гмиро В.Е., Сердюк С. Е., Поиск избирательных блокаторов NMDA и АМРА/каинатных рецепторов в ряду бис-аммониевых соединений с адамантильными радикалами. Экспер и клин. Фармакологи. Т.63(1), С. 7−13 (2000).
- Григорьев В.В., Драный О. А., Бачурин С. О. Сравнительное исследование механизма действия препаратов димебона и мемантина на АМРА- и NMDA-подтипы глутаматных рецепторов нейронов головного мозга крыс. БЭБ и мед. Т. 136, № 11, С. 535−538 (2003).
- Григорьев В.В. Автореф. дис. док. наук, Москва (2009).
- Гудашева Т.А., Кирьянова Е. П., Колик Л. Г., Константинопольский М. А., Середеннн С. Б. Дизайн и синтез дипептидных аналогов холецистокинина-4 с анксиолитической и анксиогенной активностью. Биоорганическая химия. Т. ЗЗ, № 4, с.413−420 (2007).
- Зефиров Н.С., Афанасьев А. З., Афанасьева С. В., Бачурин С. О., и др. Средство для лечения болезни Альцгеймера. Патент РФ № 2 106 864 (зарегистрирован в Гос. реестре изобретений 20.03.1998.
- Зиньковская Л. Я., Кидин Ю. В., Комиссаров И. В., Образцова О. Г. Отсутствие антидепрессантоподобной активности лигандов полиамин-связываютцих участков NMDA-рецепторов на модели депрессии. Экспер. и клин, фармакол. Т. 69(1). с. 3−5 (2006).
- Караджаев Ш. Автореф. дисс. канд. наук, Москва (1998).
- Касьян Л.И., Касьян А. О., Голодаева Е. А. Журн. органич. химии (2000).
- Ковалев Г. И. Автореф. дис. док. наук, Москва (1993).
- Ковалев Г. И. Фирстова Ю.Ю., Салимов P.M., Влияние пирацетама и ацефепа на NMDA и никотиновые рецепторы мозга мышей с различной эффективностьюисследовательского поведения в крестообразном лабиринте. Экспер. и клин, фармакол. Т. 71(1), с. 12−17 (2007).
- Комиссаров И.В. Синаптические ионотропные рецепторы и познавательная деятельность. Донецк.: изд. Донецк, мед. универ. С. 99- 110 (2001).
- Лермантова Н.Н., Редкозубое А. Е., Шевцова Е. Ф. и др. Димебон и такрин ингибируют нейротоксическое действие р-амилоида в культуре и блокируют Са2±каналы L-типа. БЭБ и мед. Т. 132, № 11, С. 545−550 (2001).
- Лермонтова Н.Н., Лукоянов Н. В., Серкова Т. П., и др. Димебон улучшает обучение животных с экспериментальной болезнью Альцгеймера. БЭБ и мед. Т. 129, № 6, С. 640−642 (2000).
- Литвинов В.П. Химия гетероциклических соединений. № 1. с. 12−39 (2002).
- Макаренко А.Н., Косицын Н. С., Карпенко С. В., Мишина В. А. Авторское свидетельство. № 1 767 518 от 03.11 (1990).
- Морозов И.С., Петров В. И., Сергеева С. А. Фармакология адамантанов. РЖ Химия. № 10, с. 19−29 (2000).
- Николлс, Дж. Мартин, А.Р. Валлас, Б.Дж. Фукс. П. А. От нейрона к мозгу. М, УРСС (2003).
- Новиков В.Е., Ковалева Л. А. Влияние препаратов с ноотроппой активностью на окислительное фосфорилирование митохондрий мозга при черепно-мозговой травме // Экспериментальная клиническая фармакология, т. 60, № 1, с. 59−61, (1997)
- Овчинников Ю. А, // Биоорганическая химия, т. 12. № 2. с. 205 (1978).
- Островская Р.У., Гудашева Т. А., Воронина Т. А., Середенин С. Б. Оригинальный ноотропный и нейропротективный препарат Ноопепт. Экспер. и клин. Фармакология, т.65, № 5, с. 66−72 (2002).
- Санин П.И. Биоорганическая химия, т.2. № 5. с. 627−631 (1975).
- Середенин С.Б. и др. Прогноз индивидуальных реакций па эмоциональный стресс и бензодиазепиновые транквилизаторы. Экспериментальная и клиническая фармакология, Т.64. № 1. С.3−12 (2001).
- Середенин С.Б., Акопян В. П., Авдюнина и др., Патент РФ № 2 288 714, Бюл.изобр. № 34 (2006).
- Фирстова Ю.Ю. Автореф. дис. канд. наук, Москва (2008).
- Alexandre S. Basso, Dan Frenkel, Francisco J. Quintana, et. al., Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis, J. Clin. Invest., 118(4), P. 1532−1543 (2008).
- Andrasi, F. Talampancl. Antiepileptic, Neuroprotectant, Skeletal muscle relaxant. Drugs of the Future, 26, 754−756 (2001).
- Aracava Y. Pereira EF, Maelicke A and Albuquerque EX (2005) Memantine blocks a7 nicotinic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther 312:1195−1205.
- Araque A., Li N., Doyle R.T., Haydon P.G. SNARE protein-dependent glutamate release from astrocytes // J. Neurosci. V.20. № 2. P. 666−673 (2000).
- Armstrong, D.D. The neuropathology of temporal lobe epilepsy. J. Neuropathol. Exp. Neurol., 52,33−443 (1985).
- Auberson, Y.P. Competitive AMPA antagonism: a novel mechanism for antiepileptice drugs? Drugs of the Future, 26, 463−471 (2001).
- Bachurin С.О., Shevtsova Е.Р., Kireeva E.G., et al. Mitochondria as a Target for Neurotoxins and Neuroprotective Agents // Ann. N.Y. Acad. Sci. 993: 334−344 (2003).
- Bai F, Bergeron M, Nelson DL. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology, 44(8), 1013−21 (2003).
- Baron В. M., Harrison B. L., KehneJ., et al., Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist// Eur.J. Pharmacol., Vol. 323, P. 181−192(1997).
- Baude A., Nusser Z., Roberts J.D. et al. The mctabotropic glutamate receptor (mGluRl alpha) is concentrated at perisynaptic membrane of neuronal subpopulations as detected by immunogold reaction //Neuron., V. l 1. № 4. P. 771−787 (1993).
- Baumbarger PJ, Muhlhauser M, Yang CR, Nisenbaum ES. LY392098, a novel AMPA receptor potentiator: electrophysiological studies in prefrontal cortical neurons. Neuropharmacology 40: 992−1002 (2001).
- Belen G. Ramirez, 1 Cristina Blazquez, 2 Teresa Gomez del Pulgar, et al., Prevention of Alzheimer’s Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation. The Journal of Neuroscience, 25(8):1904−1913 (2005).
- Bennett J., Dingledine R. Topology profile for a glutamate receptor: three transmembrane domains and a channel-lining reentrant membrane loop // Neuron, v. 14, p. 373−384,(1995)
- Bichoy H. Gabra, Fay K. Kessler, et al. Decrease in N-Methyl-D-aspartic Acid Receptor-NR2B Subunit Levels by Intrathecal Short-Hairpin RNA Blocks Group I Metabotropic Glutamate Receptor-Mediated Hyperalgesia. JPET 322:186−194 (2007).
- Boulter J, Hollmann M, O’Shea-Greenfield A, et al. Molecular cloning and functional expression of glutamate receptor subunit genes. Science (Wash DC) 249: 1033−1037 (1990a).
- Bowie, D, and Mayer, M. L. Inward rectification of both AMPA and kainite subtype glutamate receptors generated by polyamine-mediated ion channel block. Neuron, 15(2), 453−62 (1995).
- Brauuner-Osborne H., Egebjerg J., Nielsen E. Ligands for Glutamate Receptors: Design and Therapeutic Prospects // J. of Med.Chem., v. 43, № 14, p. 2609 2644, (2000)
- Broutman Greg and Baudry Michel. Involvement of the Secretory Pathway for AMPA Receptors in NMDA-Induced Potentiation in Hippocampus // The Journal of Neuroscience, 21(l):27−34 (2001).
- Brown R.E., Stevens D.R., Haas H.L.// Prog. Neurobiol. Vol. 63, N 6. P. 637−672 (2001).
- Chapman A.G., Glutamate receptors in epilepsy. Prog. Brain Res., 116, 371−383 (1998).
- Chaudhry F.A., Lehre K.P., van Lookeren Campagne M. et al. Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry // Neuron. V.15. № 3. P. 711 720. (1995).
- Chen HS and Lipton SA The chemical biology of clinically tolerated NMDAreceptor antagonists. J Neurochem 97:1611−1626 (2006).
- Choi D., Calcium: still center-stage in hipoxic ischemic neuronal death // Trends neuroscience, v. 18, p. 58 — 60, (1995)
- Chui D.W. Calcium: still center-stage in hypoxic-ischemic neuronal death // Trends Neurosci. Vol. 18. P.58−60 (1995).
- Claus J., Ludwig C., Mohr E. Nootropics drugs in Alzheimers disease: sympotomatic. treatment with pramiracetam // Neurology., v. 41, p. 570 574, (1991)
- Clements JD, Feltz A, Sahara Y and Westbrook GL Activation kinetics of AMPA receptor channels reveal the number of functional agonist binding sites. J Neurosci 18: 119−127(1998).
- Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol Toxicol., 37:205−237 (1997).
- Conti F., Weinberg RJ. Shaping excitation at glutamatergic synapses // Trends Neurosci., 22, 451−458, (1998)
- Cossart R., Epsztein J., Tyzio R. et al. Quantal release of glutamate generates pure kainate and mixed AMPA/kainate EPSCs in hippocampal neurons // Neuron. V.35. № l.P. 147−159 (2002).
- Cossart, R., Esclapez, M., Hirsch, J. C., et al. GluR5 kainate receptor activation in interneurons increases tonic inhibition of pyramidal cells. Nat Neurosci, 1(6), 470−8 (1998).
- Cossart, R., Tyzio, R., Dinocourt, C., et al. .Presynaptic kainate receptors that enhance the release of GABA on CA1 hippocampal interneurons. Neuron, 29(2), 497−508 (2001).
- Cull-Candy, S., Brickley, S., and Farrant, M. Curr. Opin. Neurobiol. 11, 327−335 (2001) Stephenson, F. A. Curr. Drug Targets 2, 233−239 (2001).
- Darlington, CL Dexanabinol: A novel cannabinoid with neuroprotective properties, IDrugs 6:976−979(2003).
- Ditzler К Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 41:773−780 (1991).
- Dreixler JC and Leonard JP Effects of external calcium on zinc modulation of AMPA receptors. Brain Res 752: 170−174(1997).
- Dringenberg H.C., De Souza-Silva M.A., Rossmuller J. et al. // J. Ncurochim., Vol. 170, N 4, P. 1750−1758(1998).
- Du J, Gray N, Falke C, et al. Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluRl synaptic expression. Ann N Y Acad Sci.- 1003:378−380 (2003).
- Ebert В., Madsen U., Soby K.K., Krogsgaard-Larsen P. Functional partial agonism at ionotropic excitatory amino acid receptors // Neurochem. Int, v. 29, p. 309 316, (1996)
- EdsHB Uylings, CG van Eden JPC De Bruin, MGP Feenstra, CMA Pennartz. Role of the Prefrontal Cortex and Limbic Structures // Amsterdam: Elsevier, 2000- 183−194.
- El-Husseini Ael D., Schnell E., Dakoji S. et al. Synaptic strength regulated by palmitate cycling on PSD-95 // Cell. V.108. № 6. P. 849−863 (2002).
- Eun Young Lee, Min Kyu Lee. Increased Labelling of Perivascular Phagocytes by Blood-Borne HRP in the SAM P10 Brain. National University, Seoul, Korean J. Anat. 34(6), 645−651 (2001).
- Eun Young Lee, Yoo-Hun Suh. Increased Labelling of Perivascular Phagocytes by Blood-Borne HRP in the SAM P10 Brain. National University, Seoul, Korean J. Anat. 35(6), 493−500 (2002).
- Fan Q.I., Hanin I. //Neurochem. Res. Vol. 24, № 1, P. 15−24 (1999).
- Feigin, V. Irampanel. Boehringer Ingelheim. Curr. Opin. Investig. Drugs, 3,908−910 (2002).
- Flood DG, Buell SJ, Horwitz GJ, Coleman PD. Dendriticextent in human dentate gyrus granule cells in normalaging and senile dementia. Brain Res- 402: 205−16 (1987).
- Fraser С. M., Cooke M. J., Fisher A., et al. Interactions between ifenprodiland dizocilpine on mouse behaviour in models of anxiety and working memory // Eur. Neuropsychopharmacol., Vol. 6. P. 311−316 (1996).
- Frerking M., Malenka R.C., Nicoll R.A. Synaptic activation of kainate receptors on hippocampal interneurons // Nat. Neurosci. V.l. № 6. P. 479−486 (1998).
- Frerking, M., Petersen, С. C., and Nicoll, R. A. Mcchanisms underlying kainate receptor-mediated disinhibition in the hippocampus. Proc Natl Acad Sci USA, 96(22), 12 917−22 (1999).
- Fujii S, Sasaki H, Mikoshiba K, Kuroda Y, et al. A chemical LTP induced by co-activation of metabotropic and N-methyl-D-aspartate glutamate receptors in hippocampal CA1 neurons. Brain Res 999: 20−28 (2004).
- Galeotti N., Ghelardini C., Pittaluga A. et al. AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram) // Naunyn-Schmiedeberg's Archives of Pharmacology V. 368, № 6 P. 538−545 (2003).
- Gardoni F and Di Luca M New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 545:2−10 (2006).
- Gareth Pryce, Zubair Ahmed, Deborah J. R. Hankey, et al., Cannabinoids inhibit neurodegeneration in models of multiple sclerosis, Brain, 126 (10), 2191−2202 (2003).
- Gasparini F, Kuhn R, Pin JP. Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Curr Opin Pharmacol, 2: 43−9 (2002).
- Gerzon, K. et al. The adamantyl group in medicinal agents. I. Hypoglycemic N-arylsulfonyl-NFtb-adamantylureas. J. Med. Chem. 6, 760−763 (1963).
- Gill R., Nordholm L., Lodge D. The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl benzo (F) quinoxaline (NBQX) in a rat focal ischaemia model // Brain Res., 580, p. 35−43, (1992)
- Gitto, R. Orlando, V. Quartarone, S. et al. Synthesis and evalution of pharmacological propoties of novel annelated 2,3-benzodiazepine derivatives. J. Med. Chem., 46, 3758−3761 (2003).
- Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia// Am J Psychiatry., L58: 1367−77 (2001).
- Gosden RG, Laing SC, Flurkey K, Finch CE: Graafian follicle growth and replacement in anovulatory ovaries of ageing C57BL/6J mice. J Reprod Fertil, 69:453−462(1983).
- Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology-29:32−38 (2004).
- Gouliaev A., Sennind A. Piracetam and other structurally related nootropics // Brain Res. Rev., v. 19, p. 180−222 (1994).
- Gray N, Du J, Falke C, Yuan P, Manji H. Lithium regulates total and synaptic expression of the AMPA glutamate receptor GluR2 in vitro and in vivo Ann N Y Acad Sci.- 1003:402−404 (2003).
- Groom A.J., Smith Т., Turski L.-Multiple sclerosis and glutamate. Ann. N. Y. Acad. Sci. 993:229−275 (2003).
- Hahm SH, Chen Y, Vinson C. Eiden LE. A calcium-initiated signaling pathway propagated through calcineurin and cAMP response element-binding protein activates proenkephalin gene transcription after depolarization. Mol Pharmacol 64:1 SOS-IS 11(2003).
- Hamelink C, Lee HW, Hsu CM, Eiden LE. Role of protein kinases in neuropeptide gene regulation by PACAP in chromaffin cells: a pharmacological and bioinformatic analysis. Ann N Y Acad Sci 971:474−490 (2002).
- He Y., Janssen W.G. Rothstein J.D., Morrison J.H. Differential synaptic localization of the glutamate transporter EAAC1 and glutamate receptor subunit GluR2 in the rat hippocampus // J. Сотр. Neurol. V.418. № 3. P. 255−269 (2000).
- Heuss C. Scanziani M, Gahwiler BH, Gerber U G-protein-independent signaling mediated by metabotropic glutamate receptors. Nat. Neurosci., 2:1070−1077 (1999).
- Higuchi, K., et al.: Purification and characterization of a senile amyloid-related antigenic substance (apoSASsANi) from mouse serum. J. Biol. Chem.- 261: 1 283 412 840. (1986).
- Hollmann M. and Heinemann S. Cloned glutamate receptors. Annu Rev Ncurosci, 17,31−108(1994).
- Jauch D" Urbanska E. M., Guidetti P., et. al., Dysfunction of brain kynurenic acid metabolism in Huntington’s disease: focus on kynurenineaminotransferases //J. Neurol. Sci. Vol. 130, P. 39−47 (1995).
- Jiang Zhao, Yi Peng, Zhuo Xu, Rong-qing Chen et al., Synaptic Metaplasticity through NMDA Receptor Lateral Diffusion. Journal of Neuroscience, 28(12):3060−3070 (2008).
- Jian-yu Lan, Vytenis A. Skeberdis, et al., Activation of Metabotropic Glutamate Reccptor 1 Accelerates NMDA Receptor Trafficking. J. Neuroscience, August 15, 21(16):6058−6068 (2001).
- Joly C, Gomeza J, Brabet I, Curry K, et al., Molecular, functional, and pharmacological characterization of the metabotropic glutamate receptor type 5 splice variants: comparison with mGluRl. J Neurosci 15:3970−3981(1995).
- Jones MV and Westbrook GL The impact of receptor desensitization on fast synaptic transmission. Trends Neurosci 19: 96−101 (1996).
- Kamiya, H., and Ozawa, S. Kainate receptor-mediated presynaptic inhibition at the mouse hippocampal mossy fibre synapse. J Physiol, 523 Pt 3, 653−65 (2000).
- Kanwar, J.R., Kanwar, R.K., Krissansen, G.W. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain. 127:13 131 331 (2004).
- Karasawa J, Shimazaki T, Kawashima N, Chaki SAMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res., 25, 1042(l):92−8 (2005).
- Karcz-Kubicha M., Jessa M., Nazar M., et al. Anxiolyticactivity of glycine-B antagonists and partial agonists — no relation to intrinsic activity inthe patch clamp // Neuropharmacology, Vol. 36, P. 1355−1367 (1997).
- Keller EA, Borghese CM, et al. The learning capacity of high or low performance rats is related to the hippocampus NMDA receptors. Brain Res.-576:162−164 (1992).
- Kerstin Lindemeyer, Jost Leemhuis, Steffcn Loffler, et al. Metabotropic Glutamate Receptors Modulate the NMDA- and AMPA-Induced Gene Expression in Neocortical Interneurons. Cerebral Cortex 16(11): 1662−1677 (2006).
- Kew JN, Kemp JA. An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. J Physiol., 512, 17−28 (1998).
- Kitaichi K., Noda Y., Hasegawa T. Acute phencyclidine induces aversion, but repeated phencyclidine induces preference in the place conditioning test in rats // Eur. J. Pharmacol., Vol.318, P. 7−9 (1996a).
- Коек W., Colpaert F. C. Use of conflict procedure in pigeons to characterize anxiolytic drug activity: Evaluation of N-methyl-D-aspartate antagonists// Life Sci., Vol. 49, P. PL37-PL42 (1991).
- Kotlinska J., Liljequist S. A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701,324., Psychopharmacoiogy, Vol. 135.,-P. 175−181 (1999).
- Krystal JH, Sanacora G, Blumberg H, et al. Glutamate and GAB A systems as targets for novel antidepressant and mood- stabilizing treatments. Mol Psychiatry. 7: S71-S80 (2002).
- Kucheryanu VG and Kryzhanovskii GN Effect of glutamate and antagonists of Nmethyl-D-aspartate receptors on experimental parkinsonian syndrome in rats. Bull Exp Biol Med V. 130:629−632 (2000).
- Kullmann D.M. Kainate receptor-dependent axonal depolarization and action potential initiation in interneurons // Nat. Neurosci. V.4. № 7. P. 718−723 (2001).
- Kullmann D.M. Spillover and synaptic cross talk mediated by glutamate and GABA in the mammalian brain // Prog. Brain Res. V.125. P. 339−351 (2000).
- KunishimaN., Shimada Y. Tsuji Y. et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor // Nature. V.407. № 6807. P. 971−977 (2000).
- Lam A.G., Soriano M.A., Monn J.A., Schoepp D.D., Lodge D., McCulloch J. Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia // Neurosci. Lett., v. 254, p. 121 -123 (1998).
- Laube В., Hirai H., Sturgess M., Betz H., Kuhse J. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit // Neuron, v. 18, p. 493 503 (1997).
- Layer R T, Popik P, Olds T, Skolmck P Antidepressant-like actions of the polyaminc site NMDA antagonist, ehprodil (SL-82 0715) //Pharmacol Biochem Behav., Vol. 52, P 621−627 (1995).
- Lerner A.J. Alzheimer’s disease: target for drug development // Mini reviews in Med. Chem, v.2, № 1, p. 1 10 (2002).
- Levite M. S" Rogers, A. Basile, Autoimmune epilepsy, Nature Immunology, 3(6), P. 500 (2002).
- Longo, F.M., Massa, S.M., Neuroprotective strategies in Alzheimer’s disease. // NeuroRx, 1,117−127 (2004).
- Longo, F.M., Massa, S.M., Neurotrophin-based strategies for neuroprotection. // J Alzheimers Dis, 6, p.13−7 (2004).
- Lujan R., Nusser Z., Roberts J.D. et al. Perisynaptic location of metabotropic glutamate receptors mGluRl and mGluR5 on dendrites and dendritic spines in the rat hippocampus // Eur. J. Neurosci., V.8. № 7. P. 1488−1500 (1996).
- Maas Al, Murray G, Henney H 3rd et al., Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial,. Lancet Neurol. Jan. V. 5(1), P. 38−45 (2006).
- Maj J, Rogoz Z, Skuza G, Sowinska H The effect of CGP 37 849 and CGP 39 551, competitive NMDA receptor antagonists, in the forced swimming test // Pol J Pharmacol Pharm, Vol 44, P. 337−346 (1996).
- Maj M. Bruno V, Dragic Z et al. (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology, V. 45, P. 895−906 (2003).
- Matsumura, A., et al.: A novel amyloid fibril protein isolated from senescence-accelerated mice // Lab. Invest., 47: 270−275. (1982).
- McCulloch J. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man // Br. J. Clin. Pharmacol., v. 34, p. 106 114, (1992).
- McMillan D. E., Hardwick W. C, deCosta B. R., Rice К. С Effects of drags that bind to PCP and sigma receptors on punished responding //J. Pharmacol. Exp. Ther., Vol. 258, P. 1015−1018(1991).
- Menniti, F.S.- Buchun, A.M.- Chenard, B.L.- et al. CP465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo. Stroke, 34, 171−176 (2003).
- Michela Giustizieri, Maria Letizia Cucchiaroni, Ezia Guatteo et al, Memantine Inhibits ATP-Dependent K+ Conductances in Dopamine Neurons of the Rat Substantia Nigra Pars Compacta, JPET 107.122 036 (2007).
- Miguel Hidalgo J.J., Alvarez X.A., Quack G., Cacabelos R. Protection by memantine against induced neurodegeneration in CA1 subfield // Neurobiol. Aging. Vol. 19. P. 542(1998).
- Miyamoto M. Kiyota Y, Nishiyama M, Nagaoka A. Senescence-accclerated mouse (SAM): Age-related reduced anxiety-like behavior in the SAM-P/8 strain. Physiol Behav- V. 51, P. 979−985 (1992).
- Miyamoto M, Kiyota Y, Yamazaki N, Nagaoka A, Matsuo T, Nagawa Y, Takeda T: Age-related changes in learning and memory in the senescence-accelerated mouse (SAM).Physiol Behav. V. 38, P. 399−406 (1986).
- Miyamoto M: Characteristics of age-related behavioral changes in senescence-accelerated mouse SAMP8 and SAMP10. Exp Gerontol, V. 32, P. 139−148 (1997).
- Moghaddam B. Bringing order lo the glutamate chaos in schizophrenia // Neuron., V. 40 (5), P. 881−4 (2003).
- Moriguchi S., Shioda N., Maejima H., et al. Nifiracetam potentiates NMDA receptor function via protein kinase С activation and reduces magnesium block of receptor// Mol. Pharmacol., V. 71, P. 580−587 (2007).
- Moryl E., Danysz W., Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane // Pharmacol. Toxicol., Vol. 72, P. 394−397 (1993).
- Nakazawa K, Mikawa S, Hashikawa T and Ito M Transient and persistent phosphorylation of AMPA-type glutamate receptor subunits in cerebellar purkinje cells. Neuron., V. 15, P. 697−70(1995).
- Narahashi Т., Moriguchi S., Zhao X., et al. Mechanism of action of cognitive enhancers on neuroreceptors // Biol. Pharm. Bull., 27 (11). P. 1701−1706 (2004).
- Nicoletti F., Bruno V., Copani A., Casabona G. Knopfel T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? // Trends Neurosci., v. 19, p. 267−271, (1996).
- O’Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord., 3(3): 181−94 (2004).
- O’Neill MJ, Murray TK, Whalley К et al. Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson’s disease. Eur J Pharmacol., V. 486(2), P. 163−74 (2004).
- Papp M., Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression // Eur. J. Pharmacol., Vol. 263.-P. 1−7 (1994).
- Papp M., Moryl E. Antidepressant-like effects of l-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression // Eur. .T. Pharmacol., Vol. 316, P. 145−151 (1996).
- Papp M., Moryl E. New evidence for the antidepressant activity of MK-801, a noncompetitive antagonist of NMDA receptors // Pol. J. Pharmacol., Vol. 45, P. 549−553 (1993).
- Parsons, C. G., Danysz, W. & Quack, G. Memantine is a clinically well-tolerated N-methyl-D-aspartate (NMDA) receptor antagonista review of the preclinical data. Neuropharmacology V. 38, p. 735−767 (1999).
- Patneau D.K., Mayer M.L. Structure-activity relationships for amino acid transmitter candidates acting at N-methyl-D-aspartate and quisqualate receptors // J. Neurosci. V.10. № 7. P. 2385−2399 (1990).
- Pellow S., Chopin P., Pile S., Briley M. Validation of open: closed arm entries in elevated plus-maze as a nuasure of anxiety in the rat // Neurosci. Meth J., № 14, p. 149- 167(1985).
- Pin J.P., Duvoisin R. The metabotropic glutamate receptors: structure and functions // Neuropharmacology, V.34. № 1. P. 1−26 (1995).
- Pittenger С and Kandel ER. In search of general mechanisms for long-lasting plasticity: aplysia and the hippocampus. Philos Trans R Soc Lond В Biol Sci V. 358, P. 757−763 (2003).
- Popoli P, Frank C, Tebano MT, et al. Modulation of glutamate release and excitotoxicity by adenosine A (2A) receptors. NeuroIogy.-6I :S69-S71 (2003).
- Quirk JC, Nisenbaum ES. LY404187: A novel positive allosteric modulator of AMPA Receptors. CNS Drug Rev- 8: 255−82 (2002).
- Rajani R.J. Shelke and Christiaan Leeuwenburgh Life-long calorie restriction (CR) increases expression of apoptosis repressor with a caspase recruitment domain (ARC) in the brain FASEB J, 2003- 10.1096.
- Reisberg, B. et al. Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med. 348, 1333−1345 (2003).
- Rodriguez-Moreno, A., Herreras, O., and Lerma, J. Kainate receptors presynaptically downregulate GABAergic inhibition in the rat hippocampus. Neuron, V. 19(4), P. 893−901(1997).
- Ross K.C., Coleman J.R. Developmental and genetic audiogenic seizure models: behavior and biological substrates // Neurosci. Biobehav. Rev. Vol. 24, P. 639—653 (2000).
- Rotham S.M., Olney J.W. Exitoxicity and the NMDA receptors // Trend Neurosci. Vol. 10. P. 299−302 (1987).
- Sager T.N., Moller A., Watjen F., Paulson O.B., Drejer J. SPD 502 (NS 1209), a new selective AMPA antagonist, reduces the infarct size in rats following permanent occlusion of the middle cerebral artery // Springer-Verlag: Berlin, p. 323 324,1999).
- Saito, Т., Takahashi, K., Nakagawa, N., et al. Deficiencies of hippocampal Zn and ZnT3 accelerate brain aging of Rat // Biochem-Biophys-Res-Commun., V. 279(2), P. 505−11 (2000).
- Schmitz, D., Frerking, M., and Nicoll, R. A. Synaptic activation of presynaptic kainate receptors on hippocampal mossy fiber synapses. Neuron, V. 27(2), P. 327−382 000).
- Schmitz, D., Mel lor, J., and Nicoll, R. A. Presynaptic kainate receptor mediation of frequency facilitation at hippocampal mossy fiber synapses. Science, V. 291(5510), P. 1972−6 (2001).
- Semyanov, A., and Kullmann, D. M. Modulation of GABAergic signaling among intemeurons by metabotropic glutamate receptors. Neuron, V. 25(3), P. 663−72 (2000).
- Semyanov, A., and Kullmann, D. M. Kainate receptor-dependent axonal depolarization and action potential initiation in interneurons. Nat Neurosci, V. 4(7), P. 718−23 (2001).
- Seredenin S.B., Neznamov G.G., Yarkova M.A. et al., The Int.J. Neuropharmacol. ll, supp. 1,275 (2008).
- Sheng M., Nakagawa T. Neurobiology: glutamate receptors on the move // Nature. V.417. № 6889. P. 601−602 (2002).
- Shigemoto R, Kinosliita A, Wada E, et al., Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci V. 17, P. 7503−7522(1997).
- Shigemoto R., Kinoshita A., Wada E. et al. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus // J. Neurosci., Y.17. № 19. P. 7503−7522 (1997).
- Shimada A, Hosokawa M, Ohta A et al. Localization of atrophy-prone areas in the aging mouse brain: comparison between the brain atrophy model SАМ-Р/10 and the normal control SAM-R/1. Neuroscience. V. 59(4), P. 859−69 (1994).
- Shimada A, Ohta A, Akiguchi I, Takeda T. Age-related deterioration in conditional avoidance task in the SAM-P/10 mouse, an animal model of spontaneous brain atrophy. Brain Res- V. 608, P. 266−272 (1993).
- Shimada A, Ohta A, Akiguchi I. Takeda T. Inbred SAM-P/10 as a mouse model of spontaneous inherited brain atrophy. J Neuropathol Exp Neurol. V. 51, P. 440−450 (1992).
- Shimada, A. M., Tsuzuki, H. Keino, M. et al. Apical vulnerability to dendritic retraction in prcfrontalneurones of ageing SAMP 10 mouse: a model ofcerebral degeneration//Neuropathology and AppliedNeurobiology V. 32, P. 1−14 (2006).
- Simon M. Manning, Delia M. et al., NMDA Receptor Blockade with Memantine Attenuates White Matter Injury in a Rat Model of Periventricular Leukomalacia Journal of Neuroscience, V. 28(26), P. 6670−6678 (2008).
- Sonkusare SK, Kaul CL and Ramarao P Dementia of Alzheimer’s disease and other neurodegenerative disorders—memantine, a new hope. Pharmacol Res V. 51, p. 1−17 (2005).
- Stephens D. N., Andrews J S. N-methyl-D-aspartate antagonists in animal models of anxiety. Frontiers in Excitatory Ammo Acid Research P 309−316(1988).
- Sukhotina I, Dravolma O. Bespalov A Place conditioning study with NMDA receptor antagonist ehprodil in mice. Eur J Pharmacol., Vol 362, P. 103−110 (1998).
- Szatkowski M., Barbour В., Attwell D. The potassium-dependence of excitatory amino acid transport: resolution of a paradox. Brain Res. V.555. № 2. P. 343−345 (1991).
- Takeda T, Hosokawa M, Higuchi K. Senescence-accelerated mouse (SAM): A novel murine model of accelerated senescence. J Am Geriatr Soc. V. 39, P. 911−919 (1991).
- Takeda T, Hosokawa M, Higuchi K: Senescence-accelerated mouse (SAM): a novel murine model of senescence. Exp Gerontol. V. 32, P. 105−109 (1997).
- Takeda T, Hosokawa M, Takeshita S, et al. A new murine model of accelerated senescence. Mech Ageing Dev. V. 17, P. 183−194 (1981).
- Takeda T: Senescence-accelerated mouse (SAM): a biogerontological resource in aging research. Neurobiol Aging, V. 20, P. 105−110 (1999).
- Takemura, M., et al.: Beta/A4 protein like immunoreactive granular structures in the brain of Senescence-Accelerated Mouse (SAM). Am. J. Pathol. V., 142, P. 1887−1897(1993).
- Takeshita, S., et al.: Spontaneous age-associated amyloidosis in Senescence-Accelerated Mouse (SAM). Mech. Ageing Devi. V. 20, P. 13−23 (1982).
- Tan SE, Wenthold RJ and Soderling TR Phosphorylation of AMPA-type glutamate receptors by calcium/calmodulin-dependent protein kinase II and protein kinase С in cultured hippocampal neurons. J Neurosci. V. 14, P. 1123−1129 (1994).
- Tarnawa I.- Farkas S.- Berzsenyi P.- Pataki A.- Andra' si, F. Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52 466 // Eur. J. Pharmacol. V. 167, p. 193- 199,(1989).
- Terry R.D., Masliah E. Synaptic pathology in the pathogenesis of Alzheimer dementia // New trends in the diagnosis and therapy of Alzheimer' disease. Springer -Verlag K.A. Jellinger eds., p. 1 8, (1994).
- Thomas J. Gould, Michael C. Lewis. Coantagonism of glutamate receptors and nicotinic acetylcholinergic receptors disrupts fear conditioning and latent inhibition of fear conditioning // Learn. Mem. V. 12, P. 389−398 (2005).
- Todd A Carter, Jennifer A Greenhall, Shigeo Yoshida, Sebastian Fuchs, Robert Helton. Anand Swaroop, David J Lockhart and Carrolee Barlow. Mechanisms of aging in senescence-accelerated mice. Genome Biology, V. 33, P. 154−163 (2005).
- Tovar K.R., Westbrook G.L. Mobile NMDA receptors at hippocampal synapses // Neuron. V.34. № 2. P. 255−264 (2002).
- Traynelis SF and Cull-Candy SG Pharmacological properties and H+ sensitivity of excitatory amino acid receptor channels in rat cerebellar granule neurones. J Physiol (Lond). V. 433, P. 727−763 (1991).
- Traynelis SF, Hartley M and Heinemann SF Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science (Wash DC). V. 268, P. 873−876 (1995).
- Ulyana Lalo, Yuri Pankratov, Frank Kirchhoff et al., NMDA Receptors Mediate Neuron-to-Glia Signaling in Mouse Cortical Astrocytes. Journal of Neuroscience. V. 26(10), P. 2673−2683 (2006).
- Vcrkhratsky, Alexei. NMDA Receptors in Glia. The Neuroscientist.Vol. 13, No. 1, 28−37 (2007).
- Vermeiren C, Hemptinne I, Vanhoutte N, et al. Loss of metabotropic glutamate receptor-mediated regulation of glutamate transport in chemically activated astrocytes in a rat model of amyotrophic lateral sclerosis. Neurochim. V. 96(3), P. 719−31(2006).
- Vilagi, I. Takacs, J. Gulyas-Kovacs, A. et al., Protective effect of the antiepileptice drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats. Brain Res. Bull. V. 59, P. 35−40 (2002).
- Vizi E. Sylvester and Kiss P. Janos. Neurochemistry and Pharmacology of the Major Hippocampal Transmitter Systems: Synaptic and Nonsynaptic Interactions. HIPPOCAMPUS. V. 8, P. 566−607 (1998).
- Volbracht C, van Beek J, Zhu C, Blomgren К and Leist M Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur J Neurosci. V. 23, P. 2611−2622 (2006).
- Voronina T.A. Nootropic drugs in Alzheimer disease treatment. New Pharmacological Strategies. In book: Alzheimer disease: therapeutic strategics -Giacobini E., Becker eds. Birkhauser. — Boston, p. 265 — 269 (1994).
- Vyklicky L, Patneau DK and Mayer ML. Modulation of excitatory synaptic transmission by drugs that reduce desensitization at AMPA/kainate receptors. Neuron. V. 7, P. 971−984 (1991).
- Wallstrom, E., et al. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J. Neurol. Sci. V. 137, P. 89−96(1996).
- Wasterlain, C.G. Fujikawa D.G. Penix, L., et al. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia, 34 Suppl. l, S37−53 (1993).
- Weier, Т.- Weinrich, M.- Brenner, M. Et al. The AMPA receptor/Na+ channel blocker BUR 56ICL is protective in a model of global cerebral ischaemia. Eur. J. Pharmacol. V. 421, P. 165−170 (2001).
- Wen Jiang, Yun Zhang, Lan Xiao, et al., Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-Iike effects J. Clin. Invest. V. 115(11), P. 3104−3116 (2005).
- Wenk G.L., Danysz W., Mobley S.L. Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat // brain Res. Vol. 655. P. 7−11 (1994).
- Wenk G.L., Danysz W., Mobley S.L. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis // Eur. J. Pharmac. Env. Tox. Pharmacol. Vol. 293. P. 267−270 (1995).
- Wenthold RJ, Petralia RS, Blahos J, II and Niedzielski AS. Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. J Neurosci. V. 16, P. 1982−1989(1996).
- WileyJ. L., Compton A. D., Holcomb J. D" et al., Effects of modulation of NMDA neurotransmission on response rate and duration in a conflictprocedure in rats, Neuropharmacology. Vol. 37, P. 1527−1534 (1998).
- WileyJ. L., Cristello A. F., Balster R. L. Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. Eur. J. Pharmacol. Vol. 294, P. 101−107(1995).
- Wisden W and Seeburg PH. Mammalian ionotropic glutamate receptors. Curr Opin Neurobiol. V. 3, P. 291−298 (1993).
- Yamada KA and Tang C-M Benzothiadiazides inhibit rapid glutamate receptor desensitization and enhance glutamatergic synaptic currents. J Neurosci. V. 13, P. 3904−3915 (1993).
- Yamaguchi, S.- Donevan, S.D.- Rogawski, M.A. Anticonvulsant activity of AMPA/kainat antagonists: comparison of GYKY 52 466 and NBQX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. V. 15, P. 179−184 (1993).
- Yin H.Z. Tang D.T. Weiss J.H. Intrathecal infusion of a Ca (2+)-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS // Exp.Neurol. 207(2): 177−85 (2007).
- Yitao Liu, Так Pan Wong, Michelle Aarts, et al., NMDA Receptor Subunits Have Differential Roles in Mediating Excitotoxic Neuronal Death Both In Vitro and In Vivo. The Journal of Neuroscience. V. 27(11), P. 2846−2857 (2007).
- Yoshimizu T, Chaki S. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem Biophys Res Commun. V. 315(2), P. 493−6 (2004).
- Yoshimizu T, Shimazaki T, Ito A, Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl). V. 186(4), P. 587−93 (2006).
- Yu SP, Sensi SL, Canzoniero LM, Buisson A, Choi DW Membrane-delimited modulation of NMDA currents by metabotropic glutamate receptor subtypes 1/5 in cultured mouse cortical neurons. J Physiol (Lond). V. 499, P. 721−732 (1997).
- Yurkewicz L., Weaver J., Bullock M.R., Marshall L.F. The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J. Neurotrauma. V. 22, P. 1428−1443(2005).